These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7749856)

  • 1. LDL physical and chemical properties in familial combined hyperlipidemia.
    Hokanson JE; Krauss RM; Albers JJ; Austin MA; Brunzell JD
    Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):452-9. PubMed ID: 7749856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.
    Hokanson JE; Austin MA; Zambon A; Brunzell JD
    Arterioscler Thromb; 1993 Mar; 13(3):427-34. PubMed ID: 8443147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
    Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.
    Venkatesan S; Cullen P; Pacy P; Halliday D; Scott J
    Arterioscler Thromb; 1993 Jul; 13(7):1110-8. PubMed ID: 8318511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.
    Hunt SC; Wu LL; Hopkins PN; Stults BM; Kuida H; Ramirez ME; Lalouel JM; Williams RR
    Arteriosclerosis; 1989; 9(3):335-44. PubMed ID: 2497719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia.
    Austin MA; Brunzell JD; Fitch WL; Krauss RM
    Arteriosclerosis; 1990; 10(4):520-30. PubMed ID: 2369363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.
    Kissebah AH; Alfarsi S; Adams PW
    Metabolism; 1981 Sep; 30(9):856-68. PubMed ID: 7266376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
    Calabresi L; Donati D; Pazzucconi F; Sirtori CR; Franceschini G
    Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
    Franceschini G; Cassinotti M; Vecchio G; Gianfranceschi G; Pazzucconi F; Murakami T; Sirtori M; D'Acquarica AL; Sirtori CR
    Arterioscler Thromb; 1994 Oct; 14(10):1569-75. PubMed ID: 7918306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic consequences of genetic heterogeneity of lipoprotein composition (lipoprotein heterogeneity).
    Brunzell JD; Chait A; Albers JJ; Foster DM; Failor RA; Bierman EL
    Am Heart J; 1987 Feb; 113(2 Pt 2):583-8. PubMed ID: 3812212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins.
    Vakkilainen J; Jauhiainen M; Ylitalo K; Nuotio IO; Viikari JS; Ehnholm C; Taskinen MR
    J Lipid Res; 2002 Apr; 43(4):598-603. PubMed ID: 11907142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy.
    Ericsson S; Eriksson M; Berglund L; Angelin B
    J Intern Med; 1992 Oct; 232(4):313-20. PubMed ID: 1402634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
    Georgieva AM; van Greevenbroek MM; Krauss RM; Brouwers MC; Vermeulen VM; Robertus-Teunissen MG; van der Kallen CJ; de Bruin TW
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.
    Veerkamp MJ; de Graaf J; Bredie SJ; Hendriks JC; Demacker PN; Stalenhoef AF
    Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):274-82. PubMed ID: 11834528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations.
    Vargas-Vázquez A; Bello-Chavolla OY; Antonio-Villa NE; Mehta R; Cruz-Bautista I; Aguilar-Salinas CA
    Lipids Health Dis; 2021 May; 20(1):46. PubMed ID: 33952259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Verseyden C; Meijssen S; Cabezas MC
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5021-9. PubMed ID: 15472200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.
    Dejager S; Bruckert E; Chapman MJ
    J Lipid Res; 1993 Feb; 34(2):295-308. PubMed ID: 8429263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.